Format

Send to

Choose Destination
Drug Discov Today. 2014 Sep;19(9):1419-26. doi: 10.1016/j.drudis.2014.04.004. Epub 2014 Apr 14.

Therapeutic strategies for treating osteolytic bone metastases.

Author information

1
INSERM U791, Université de Nantes, Faculté de Chirurgie Dentaire, 44042 Nantes, France. Electronic address: elise.verron@univ-nantes.fr.
2
Univ Nice Sophia Antipolis, CNRS, iBV, UMR7277, UFR Médecine, 06107 Nice Cedex 2, France.
3
Hopital Pitié-Salpétrière, Service de Chirurgie, 75 651 Paris Cedex, France.
4
INSERM U791, Université de Nantes, Faculté de Chirurgie Dentaire, 44042 Nantes, France.

Abstract

The recent progress in oncologic management of patients with localized cancer or metastatic disease has permitted a significant improvement in life expectancy. Nevertheless, bone metastases and their consequent skeletal-related events (SREs) are still associated with unfavorable prognosis and greatly affect quality of life. Global management of these bone metastases includes traditional local approaches (surgery, radiotherapy, etc.) and systemic administration of chemotherapeutic agents. This review focuses on treatments specific for bone metastases and, in particular, on inhibitors of bone resorption that are effective for preventing and delaying the development of SREs.

PMID:
24742971
DOI:
10.1016/j.drudis.2014.04.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center